Overall, our data demonstrates that dual targeting of JAK2 and ERK1/2 effectively addresses ERK1/2 kinases as a second node of oncogenic signaling, which warrants inhibition in MPN. This evidence concerns the gene JAK2 and myeloproliferative disorder.